HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael A Jakupec Selected Research

Ligands

3/2024Investigating the anticancer potential of 4-phenylthiazole derived Ru(II) and Os(II) metalacycles.
1/2020Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles.
6/2019Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group.
8/2016Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems.
6/2015Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadium-Synthesis, structure and bioactivity of the vanadium complex.
9/2013Dicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution.
3/2013Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development.
12/2012Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands.
12/2012A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines.
9/2012Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael A Jakupec Research Topics

Disease

85Neoplasms (Cancer)
03/2024 - 01/2002
25Carcinoma (Carcinomatosis)
11/2022 - 01/2005
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2020 - 08/2008
7Colorectal Neoplasms (Colorectal Cancer)
02/2024 - 01/2004
7Colonic Neoplasms (Colon Cancer)
01/2021 - 01/2004
6Teratocarcinoma
03/2023 - 12/2015
3Ovarian Neoplasms (Ovarian Cancer)
07/2015 - 01/2004
2Lymphoma (Lymphomas)
12/2022 - 01/2004
2Leukemia
12/2022 - 12/2021
2Non-Hodgkin Lymphoma (Lymphosarcoma)
12/2022 - 01/2004
2Neoplasm Metastasis (Metastasis)
12/2021 - 08/2015
2Leukemia L1210
01/2017 - 01/2014
1Inflammation (Inflammations)
09/2023
1Hypersensitivity (Allergy)
12/2021
1Breast Neoplasms (Breast Cancer)
01/2020
1Hypoxia (Hypoxemia)
04/2016
1Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2016

Drug/Important Bio-Agent (IBA)

24Cisplatin (Platino)FDA LinkGeneric
09/2023 - 01/2005
20PlatinumIBA
05/2023 - 01/2004
20RutheniumIBA
01/2022 - 08/2005
17LigandsIBA
03/2024 - 01/2004
13Oxaliplatin (Eloxatin)FDA LinkGeneric
11/2023 - 01/2004
10MetalsIBA
01/2022 - 01/2004
9GalliumIBA
12/2022 - 01/2002
8OsmiumIBA
01/2022 - 08/2008
6DNA (Deoxyribonucleic Acid)IBA
11/2023 - 08/2010
5IndazolesIBA
01/2019 - 05/2007
5indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA
07/2014 - 08/2005
54-cymene (p-cymene)IBA
07/2013 - 05/2009
4Proteins (Proteins, Gene)FDA Link
12/2019 - 12/2009
4diphenyl (biphenyl)IBA
03/2013 - 10/2008
3IronIBA
01/2024 - 01/2004
3Antineoplastic Agents (Antineoplastics)IBA
12/2021 - 11/2006
3KP 1339IBA
08/2021 - 08/2015
3SodiumIBA
01/2019 - 06/2015
3ProdrugsIBA
09/2017 - 07/2015
3Coordination ComplexesIBA
08/2016 - 01/2009
3CationsIBA
11/2009 - 01/2004
2IridiumIBA
01/2022 - 01/2020
2RhodiumIBA
01/2022 - 01/2020
2IsotopesIBA
01/2021 - 06/2014
23-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA
03/2014 - 01/2010
2CopperIBA
11/2013 - 09/2012
2paulloneIBA
11/2013 - 09/2012
2QuinolinesIBA
09/2013 - 08/2010
2CymenesIBA
03/2013 - 11/2009
2Transferrin (beta 2 Transferrin)IBA
02/2013 - 11/2006
2BenzazepinesIBA
12/2011 - 08/2010
2BromidesIBA
10/2009 - 12/2008
2Ruthenium CompoundsIBA
08/2008 - 06/2007
2tris(8-quinolinolato)gallium (III)IBA
11/2006 - 01/2004
2Transferrin Receptors (Transferrin Receptor)IBA
01/2004 - 01/2004
2gallium nitrateFDA Link
01/2004 - 01/2004
2Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
01/2004 - 01/2004
1MicroplasticsIBA
02/2024
1Polystyrenes (Polystyrene)IBA
02/2024
1VLX600IBA
01/2024
1Anti-Inflammatory Agents (Anti-Inflammatories)IBA
09/2023
1PAMAM StarburstIBA
05/2023
1Dendrimers (Dendrons)IBA
05/2023
1Protective AgentsIBA
12/2022
1Vincristine (Oncovin)FDA LinkGeneric
12/2022
1Daunorubicin (Cerubidine)FDA LinkGeneric
12/2022
1quinone (benzoquinone)IBA
11/2022
1phthiocolIBA
11/2022
1Oxidoreductases (Dehydrogenase)IBA
11/2022
1NAD (NADH)IBA
11/2022
1Reactive Oxygen Species (Oxygen Radicals)IBA
11/2022
1ApatitesIBA
12/2021
1Diphosphonates (Bisphosphonates)IBA
12/2021
1Therapeutic UsesIBA
01/2021
1ElementsIBA
01/2021
1Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
01/2021
1polyanionsIBA
03/2020
1EnzymesIBA
01/2020
13-hydroxy-2-methyl-4H-pyran-4-thioneIBA
01/2020
1Adenosine Triphosphate (ATP)IBA
01/2019
1CalreticulinIBA
01/2019
1PlectinIBA
01/2017
1SolutionsIBA
11/2016
1Platinum Compounds (Compounds, Platinum)IBA
04/2016
1FlavonoidsIBA
01/2016
1Type II DNA Topoisomerases (Topoisomerase II)IBA
01/2016
1diacetyldichlorofluoresceinIBA
01/2016
1NKP-1339IBA
01/2016
1LanthanumIBA
08/2015
1acetyl acetonate (acetylacetonate)IBA
06/2015
1VanadiumIBA
06/2015
1Vanadates (Orthovanadate)IBA
06/2015
1phosphoramidic acidIBA
07/2014
1Activating Transcription FactorsIBA
03/2014
11,2-cyclohexanediamine (dach)IBA
01/2014
1TEMPOIBA
11/2013
1Peptides (Polypeptides)IBA
07/2013

Therapy/Procedure

7Therapeutics
12/2022 - 01/2004
4Drug Therapy (Chemotherapy)
03/2018 - 01/2004
2Aftercare (After-Treatment)
01/2017 - 04/2015
1Laser Therapy (Surgery, Laser)
11/2020
1Oral Administration
01/2017
1Lasers (Laser)
06/2014